Mikhail Blagosklonny: A Renowned Oncologist

Mikhail Blagosklonny is presently a scientist who is taking studies on cancer and aging. Before, Mikhail was specializing in oncology in the Roswell Institute, New York City. His academic qualifications are worth recognizing for he holds a degree in internal medicine and a doctorate in experimental medicine and cardiology. Mikhail started his career back in the New York Medical College as an associate professor in 2002. Later, he joined the Ordway Institute working as a senior scientist until 2009. He later became the professor of oncology at the Roswell Park Cancer Institute.

Due to his unending passion and dedication towards his career, Mikhail has been involved in a lot of research in the medical field. He engineered a research on cancer and its therapies when it comes to protecting normal body cells. He also led in the development of superior mechanisms and the making of anti-aging drugs. In cancer treatment, Mikhail has always advised people on the use of Rapamycin. Follow Mikhail on Google Scholar

Other than causing an impact on the field of medicine practically, Mikhail has also been actively involved in the editing of medicine-related research. Mikhail has championed writing on aging, cell cycle, and oncotarget. He has written books on the therapies of cancer and also in cells differentiation.

In one of the latest works on aging, he rules out the fact that aging is caused by the accumulation of molecular damage. He argues that aging is as a result of changes occurring in the deoxyribonucleic protein molecule. Mikhail boasts development of the hyper-function theory. He strongly believes that it is possible to control aging and cancer using the Rapamycin treatment. This treatment converts normal cells into senescent cells without any change of form of their molecular nature.

In one of his works on oncology, Mikhail states that due to the increased research on cancer and cancer-related therapies, there is an increase in the influx of knowledge. This will in turn force increased workforce that will help in the translation of the complex cancer knowledge to a normal clinical language. This will help in making it more understandable, and researchers will be able to deal with a large amount of data ensuring intensified research.

Mikhail’s other name in the research industry is Misha. Many researchers see him as a boost in the research sector. They believe that he is taking the search for new advanced strategies of cancer and aging to the next level. He has managed to publish at least 300 copies of research articles bearing his name. In the PLOS ONE, an American pathology industry, he is also involved in a lot of writing and research. Mikhail is seen as one who has a great love for humanity. In enthusiasm, he carries a great vision with him of seeing the world become a community with no trace of diseases.

Through hard work and great commitment in his passionate career, Mikhail Blagosklonny has been in the forefront to address issues of disease mitigation, and this has seen him make myriads of successful steps in his profession. Visit healingmagic.net to know more about Mikhail

Eric Lefkofksy believes plummeting cost of gene sequencing may lead to cancer cure

As one indication of the breakneck speed of technological development, it’s instructive to look at the incredible reduction in costs of sequencing human genomes. In 2003, the year that the first complete individual human genome was sequenced, the cost to do so was over $100,000,000. Fast forward 14 years, and the cost of sequencing all of an individual’s genes is a relatively paltry $5,000. This is a quantum leap forward in the accessibility of gene sequencing.

But one man, Eric Lefkofsky, believes that not only will gene sequencing play a star role in future cancer research and treatment but that the cost of sequencing individual genomes will continue to plummet, possibly reaching less than $100 in the next decade. At these price levels, essentially every American’s genome could be easily and cheaply sequenced, leading to an explosion in potentially invaluable data that may lead cancer research to the point of finding a virtual cure.

While Lefkofsky is highly optimistic about the development of cheap gene sequencing and the likely impact that it will have on cancer research and treatment, he still urges caution about the expectations of exactly what such a wealth of new information will likely bring. Lefkofsky says that it is still not hugely likely that a universal cure will be found for all types of cancers. They are simply too heterogeneous, with some cancer types being notoriously resistant to treatment.

Instead, Lefkofsky envisions the coming decades bringing better and better treatments for certain subtypes of cancer. For example, cancers that already have solidly performing, well established treatment regimens, such as breast cancer or prostate cancer, may see additional advances that will all but constitute an actual cure. With others, Lefkofksy believes, treatments may advance to the point where having the disease is similar to those in advanced countries living with AIDS. These cancers will still be a serious disease, but with closely following their treatment regimen, those living with these cancers may be able to effectively survive indefinitely, dying from an unrelated cause.

Lefkofsky says that, while these outcomes would not technically amount to a cure, they are exciting enough to motivate an entire generation of research.

for more info: chicagoinno.streetwise.co/2016/07/22/eric-lefkofskys-next-move-curing-cancer-at-tempus/